Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001

STRO-001 is a site-specific, predominantly single-species, fully human, aglycosylated anti-CD74 antibody-drug conjugate incorporating a non-cleavable linker-maytansinoid warhead with a drug-antibody ratio of 2 which was produced by a novel cell-free antibody synthesis platform. We examined the poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Abrahams, Cristina L., Li, Xiaofan, Embry, Millicent, Yu, Abigail, Krimm, Stellanie, Krueger, Sarah, Greenland, Nancy Y., Wen, Kwun Wah, Jones, Chris, DeAlmeida, Venita, Solis, Willy A., Matheny, Shannon, Kline, Toni, Yam, Alice Y., Stafford, Ryan, Wiita, Arun P., Hallam, Trevor, Lupher, Mark, Molina, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340874/
https://www.ncbi.nlm.nih.gov/pubmed/30701025
http://dx.doi.org/10.18632/oncotarget.26491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340874/
https://www.ncbi.nlm.nih.gov/pubmed/30701025
http://dx.doi.org/10.18632/oncotarget.26491

Ejemplares similares